Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count

Leukemia

Volumn 27, Issue 11, 2013, Pages 2259-2262

  Vaitkeviciene, G ^a,b   Heyman, M ^c   Jonsson, O G ^d   Lausen, B ^b   Harila Saari, A ^e   Stenmarker, M ^f   Taskinen, M ^g   Zvirblis, T ^a   Asberg A ^h   Groth Pedersen, L ^b   Rageliene, L ^a   Schmiegelow, K ^b,i  

^a VILNIUS UNIVERSITY   (Lithuania)

^b University of Copenhagen   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f RYHOV COUNTY HOSPITAL   (Sweden)

^g UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^h TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTILEUKEMIC AGENT; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; URATE OXIDASE; URIC ACID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BLOOD VISCOSITY; BRAIN EDEMA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CHILDHOOD MORTALITY; EXCHANGE BLOOD TRANSFUSION; FEMALE; HERNIA; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INFANT; LETTER; LEUKAPHERESIS; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOSTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NEUTROPENIA; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MORBIDITY; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE;

EID: 84887317608     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.137     Document Type: Letter

References (14)

1. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M et al. Risk-adjusted therapy of acute lymphobastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
2. Vaitkeviciene G, Forestier E, Hellebostad M, Heyman M, Jonsson OG, Lahteenmaki PM et al. High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies. Eur J Haematol 2011; 86: 38-46.
3. Lund B, Asberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2011; 56: 551-559.
4. Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund JT. Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 2005; 45: 10-15. (Pubitemid 40791739)
5. Renyi I, Bardi E, Udvardi E, Kovacs G, Bartyik K, Kajtar P et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. Pathol Oncol Res 2007; 13: 57-62. (Pubitemid 46883548)
6. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82: 160-165. (Pubitemid 36700996)
7. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
8. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704. (Pubitemid 32119083)
9. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
10. Eguiguren JM, Schell MJ, Crist WM, Kunkel K, Rivera GK. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. Blood 1992; 79: 871-875.
11. Harousseau JL, Tobelem G, Schaison G, Chastang C, Auclerc MF, Weil M et al. High risk acute lymphocytic leukemia: a study of 141 cases with initial white blood cell counts over 100,000/cu mm. Cancer 1980; 46: 1996-2003. (Pubitemid 10025475)
12. Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 1590-1595. (Pubitemid 16199210)
13. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11. (Pubitemid 39331101)
14. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ ctc.htm15-10-2013. 3-1-2013.